Opinion
Civil Action 17-2044 18-md-2848 MDL 2848
12-14-2022
IN RE ZOSTAVAX (ZOSTER VACCINE LIVE) PRODUCTS LIABILITY LITIGATION THIS DOCUMENT RELATES TO: DAVID R. ELMEGREEN as Trustee of THE SUE A. ELMEGREEN TRUST v. MERCK & CO., INC., et al.
PRETRIAL ORDER NO. 461
Harvey Bartle III J.
AND NOW, this 14th day of December, 2022, for the reasons set forth in the foregoing Memorandum, it is hereby ORDERED that:
(1) the judgment of the Clerk awarding costs in favor of Merck & Co., Inc. and Merck, Sharp & Dohme Corp.(“Merck”) and against plaintiff David R. Elmegreen as Trustee of The Sue A. Elmegreen Trust (Doc. # 75) is AFFIRMED IN PART AND REVERSED IN PART; and
Defendant Merck Sharp & Dohme Corp. is now known as Merck Sharp & Dohme LLC.
(2) costs are taxed in favor of Merck and against David R. Elmegreen as Trustee of The Sue A. Elmegreen Trust in the amount of $13,627.36.
BY THE COURT: